Trials / Completed
CompletedNCT03239171
Bioinformation Therapy for Lung Cancer
Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Lung Cancer
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable lung cancer.
Detailed description
By enrolling patients with unresectable lung cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Cancer ablation | Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound. |
| DRUG | Life information rehabilitation therapy | Each treatment: one bottle solution each day, consecutive 3 months, oral administration |
Timeline
- Start date
- 2017-09-02
- Primary completion
- 2018-09-02
- Completion
- 2018-09-02
- First posted
- 2017-08-03
- Last updated
- 2019-01-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03239171. Inclusion in this directory is not an endorsement.